Related Experiment Videos
Fluoxetine for migraine prophylaxis: a double-blind trial
C C d'Amato1, V Pizza, T Marmolo
1Headache Center, Neurological Institute, Second University of Naples, Italy.
Headache
|March 31, 2001
Summary
Selective serotonin reuptake inhibitors, like fluoxetine, show promise in preventing migraine headaches. This study found fluoxetine significantly reduced migraine pain compared to placebo.
Area of Science:
- Neurology
- Pharmacology
Background:
- Selective serotonin reuptake inhibitors (SSRIs) are increasingly explored for migraine treatment.
- Migraine is a debilitating neurological condition affecting millions worldwide.
Purpose of the Study:
- To evaluate the safety and efficacy of fluoxetine for migraine prevention.
- To assess fluoxetine's impact on migraine pain index.
Main Methods:
- A 6-month, randomized, double-blind, placebo-controlled study involving 52 migraine patients.
- Patients received either 20 mg/day of fluoxetine or a placebo.
- Pain levels were monitored monthly using a total pain index.
Main Results:
- The fluoxetine group showed a statistically significant reduction in the total pain index starting from the third month of treatment (P < .05).
- No significant pain reduction was observed in the placebo group.
- Fluoxetine was generally well-tolerated, with no pathological findings reported.
Conclusions:
- Preliminary findings suggest fluoxetine may be effective in the prophylactic treatment of migraine.
- Further research is warranted to confirm these results and establish optimal use.